| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC9829 | IPI-549 Featured | IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. |
|
| DCAPI1573 | Ipragliflozin (ASP1941) Featured | Ipragliflozin (ASP1941) is a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects |
|
| DC7609 | Isatoribine | Isatoribine is a selective agonist of TLR7 |
|
| DC5107 | SB-715992 (Ispinesib) Featured | Ispinesib (SB 715992) is a potent mitotic kinesin KSP (Eg5) inhibitor with a Ki and an IC50 of 0.6 and 4.1 nM, respectively. |
.gif)
|
| DC12378 | Itacitinib(INCB039110) Featured | Itacitinib is a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis. |
|
| DCAPI1366 | Itraconazole (Sporanox) | Itraconazole (Sporanox) |
|
| DC4128 | Ivacaftor (VX-770) Featured | Ivacaftor (VX-770, Kalydeco) is a potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively. |
|
| DCAPI1510 | Ixabepilone Featured | Ixabepilone (Azaepothilone B; BMS 247550) is an epothilone B analog and nontaxane microtubule-stabilizing compound with clinical activity in a range of solid tumors. |
|
| DC8379 | JH-II-127 Featured | JH-II-127 is a highly potent, selective, and brain penetrant LRRK2 inhibitor. |
|
| DC12374 | JNJ-10229570 Featured | JNJ-10229570 (JNJ10229570) is a novel potent, selective melanocortin receptor MC1R and MC5R antagonist with binding IC50 of 270 nM and 200 nM, respectively. |
|
| DC11115 | JNJ-26489112 | JNJ-26489112 (JNJ26489112) is a broad-spectrum anticonvulsant that displays activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures. |
|
| DC7175 | JNJ-26854165 (Serdemetan) Featured | JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. |
|
| DC7177 | JNJ 38877605 Featured | JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. |
|
| DC9662 | JNJ-42165279 Featured | JNJ-42165279 is a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 70nM. |
|
| DC12271 | JNJ-54175446 Featured | JNJ-54175446 is a potent and selective brain penetrant P2X7 receptor antagonist, with pIC50s of 8.46 and 8.81 for hP2X7 receptor and rP2X7 receptor, respectively. |
|
| DC11080 | JPI-289 | JPI-289 (JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM. |
|
| DC11190 | JTT-551 | JTT-551 (JTT551, JTT 551) is a novel potent, selective inhibitor of protein tyrosine phosphatase 1B (PTP1B) with Ki of 0.22 uM, displays >45-fold and >136-fold selectivity over TCPTP, CD45 and LAR. |
|
| DC11191 | JTT-551 sodium | JTT-551 sodium (JTT551, JTT 551) is a novel potent, selective inhibitor of protein tyrosine phosphatase 1B (PTP1B) with Ki of 0.22 uM, displays >45-fold and >136-fold selectivity over TCPTP, CD45 and LAR. |
|
| DC9272 | K 858 Featured | K 858 is an ATP-uncompetitive mitotic kinesin Eg5 inhibitor, which does not effect microtubule dynamics. |
|
| DC8247 | KNK437 Featured | KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40. |
|
| DC10487 | KO947 Featured | KO-947 is a small molecule inhibitor of extracellular-signal-regulated kinases 1 and 2 (ERK1/2), as a potential treatment for cancers in which the mitogen activated protein kinase (MAPK) pathway. |
|
| DC9788 | KP1019(FFC14A) | KP1019 (FFC14A) is just the second ruthenium-based anticancer agent after NAMI-A which was developed to the stage of clinical trials. |
|
| DC7067 | KPT-330(Selinexor) Featured | KPT-330, analog of KPT-185, is an orally bioavailable selective CRM1 inhibitor. |
|
| DC10454 | KRN633 Featured | KRN633 is a potent and selective VEGFR inhibitor. which inhibits tyrosine phosphorylation of VEGFR-2 (IC50 = 1.16 nmol/L) in human umbilical vein endothelial cells. |
|
| DC8522 | KW-2449 Featured | KW 2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase. |
|
| DC7449 | KW-2478 Featured | KW-2478 is a nonansamycin HSP90 inhibitor with IC50 of 3.8 nM. Phase 1/2 |
|
| DC8023 | KX2-391 Featured | KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. |
|
| DC8159 | L-701,324 Featured | L-701,324 is a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. |
|
| DC8797 | Lacosamide Featured | Lacosamide (Vimpat; Erlosamide) is a medication developed for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. |
|
| DCAPI1512 | Lapatinib Featured | Lapatinib |
|
